1. Home
  2. SLM vs IMVT Comparison

SLM vs IMVT Comparison

Compare SLM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLM Corporation

SLM

SLM Corporation

HOLD

Current Price

$22.62

Market Cap

5.4B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.65

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLM
IMVT
Founded
1972
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.3B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SLM
IMVT
Price
$22.62
$26.65
Analyst Decision
Buy
Buy
Analyst Count
11
9
Target Price
$32.45
$30.78
AVG Volume (30 Days)
3.2M
1.3M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
2.30%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.10
N/A
Revenue Next Year
$6.16
N/A
P/E Ratio
$6.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.50
$12.72
52 Week High
$34.55
$27.92

Technical Indicators

Market Signals
Indicator
SLM
IMVT
Relative Strength Index (RSI) 26.03 50.00
Support Level $23.85 $25.09
Resistance Level $27.51 $27.08
Average True Range (ATR) 0.90 1.21
MACD -0.39 -0.02
Stochastic Oscillator 2.06 53.69

Price Performance

Historical Comparison
SLM
IMVT

About SLM SLM Corporation

SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: